Table 8.
Summary | Phase 1 | Phase 3 | Comparison of NAI or NXN between phasesb |
---|---|---|---|
Total participants (n) | 42 | 42 | |
NAI total time to complete critical tasks (min)a | |||
N | 42 | 42 | <0.0001 |
Mean (SD) | 0.9 (0.25) | 0.5 (0.15) | |
Median | 0.9 | 0.5 | |
Min, Max | 0.5, 1.5 | 0.3, 0.9 | |
NXN total time to complete critical tasks (min)a | |||
N | 42 | 42 | <0.0001 |
Mean (SD) | 6.0 (4.76) | 2.0 (2.15) | |
Median | 3.6 | 1.6 | |
Min, Max | 1.8, 15.0 | 0.8, 15.0 | |
Comparison of NAI and NXN within each phaseb | <0.0001 | <0.0001 |
NAI naloxone 0.4 mg auto-injector, NXN naloxone nasal atomization kit
aSubject not completing the task counted as 15 min
bWilcoxon rank-sum test performed as sensitivity analysis